Abstract
Antigen-specificity of T cells provides important clues to the pathogenesis of T cell-mediated autoimmune diseases and immune-evasion strategies of tumors. Identification of T cell clones involved in autoimmunity or cancer is achieved with soluble peptide-MHC (pMHC) complex multimers. Importantly, these complexes can also be used to manipulate disease-relevant T cells to restore homeostasis of T cell-mediated immune response. While auto-antigen-specific T cells can be deleted or anergized by T cell receptor engagement with cognate pMHC complexes in the absence of costimulation, integration of these complexes in artificial antigen-presenting systems can activate tumor antigen-specific T cells. Here the authors discuss the advancements in pMHC-complex-mediated immunotherapeutic strategies in autoimmunity and cancer and identify the lacunae in these strategies that need to be addressed to facilitate clinical implementation.
| Original language | English |
|---|---|
| Pages (from-to) | 337-350 |
| Number of pages | 14 |
| Journal | Immunotherapy |
| Volume | 14 |
| Issue number | 5 |
| DOIs | |
| State | Published - Apr 2022 |
Funding
The authors would like to thank SERB, Govt. of India (ECR/2017/002073) for funding this research. This work was supported by the School of Medical Science and Technology, Indian Institute of Technology, Kharagpur, India. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. The authors would like to thank SERB, Govt. of India (ECR/2017/002073) for funding this research.
Keywords
- antigen-specific immunotherapy
- artificial antigen-presenting systems
- autoimmunity
- cancer
- peptide-MHC multimers